RTP Mobile Logo
What Advanced Practice Professionals Need to Know about Caring for Patients with Locally Advanced Non-Small Cell Lung Cancer (Webinar Audio Proceedings)
Released December 2020

Featuring perspectives from Dr Ramaswamy Govindan, Dr Matthew Gubens, Ms Alison Holmes Tisch and Ms Rasheda Persinger. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of advanced practice professionals, including nurse practitioners and physician assistants, involved in the treatment of locally advanced non-small cell lung cancer (NSCLC).

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.

    LEARNING OBJECTIVES

    • Appreciate the benefits, risks and long-term outcomes associated with current local and/or systemic treatment modalities in the management of resectable or unresectable locally advanced NSCLC, and consider this information when counseling patients.
    • Review anti-PD-L1 antibody therapy as consolidation for patients with unresectable Stage III NSCLC who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
    • Develop an understanding of which clinical and biologic factors (eg, chemoradiation therapy-related toxicities, PD-L1 status, EGFR and ALK status) potentially affect the decision to use anti- PD-L1 antibody consolidation therapy for unresectable Stage III NSCLC, and apply this information to better counsel patients about current therapeutic recommendations.
    • Recognize immune-related adverse events and other common side effects of anti-PD-L1 antibody consolidation therapy in patients with Stage III NSCLC, and offer supportive strategies to minimize and manage these toxicities.
    • Identify opportunities to enhance the collaborative role of oncology nurses, nurse practitioners and physician assistants in the comprehensive biopsychosocial care of patients with locally advanced NSCLC to optimize clinical and quality-of-life outcomes.

    ACCREDITATION STATEMENTS
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    CME CREDIT DESIGNATION STATEMENTS
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NCPD CREDIT DESIGNATION STATEMENTS
    Audio Program: This educational activity for 1.75 contact hours is provided by RTP during the period of December 2020 through December 2021.

    This activity is awarded 1.75 ANCC pharmacotherapeutic contact hours.

    Video Program: This educational activity for 1.25 contact hours is provided by RTP during the period of December 2020 through December 2021.

    This activity is awarded 1.25 ANCC pharmacotherapeutic contact hours.

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20.

    FOR SUCCESSFUL COMPLETION
    Audio Program: To receive credit, participants should read the learning objectives and faculty disclosures, listen to the mp3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/CNE. The corresponding video program is available as an alternative at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/Video.

    Video Program: To receive credit, participants should read the learning objectives and faculty disclosures, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20/Video/CNE. The corresponding audio program is available as an alternative at ResearchToPractice.com/LocallyAdvancedNSCLCAPP20.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME and NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ramaswamy Govindan, MD
    Professor of Medicine
    Director, Section of Oncology
    Anheuser-Busch Endowed Chair in Medical Oncology
    Washington University School of Medicine
    St Louis, Missouri

    Advisory Committee: Achilles Therapeutics; Consulting Agreements: GenePlus, Horizon Pharmaceuticals.

    Matthew Gubens, MD, MS
    Associate Professor, Thoracic Medical Oncology
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: AstraZeneca Pharmaceuticals LP, BeyondSpring Inc, Bristol-Myers Squibb Company, Inivata; Contracted Research: Celgene Corporation, Merck, Novartis, OncoMed Pharmaceuticals Inc, Roche Laboratories Inc.

    Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP
    Clinical Operations Manager
    Thoracic, Neuro, Uro and Radiation Oncology
    Nurse Practitioner, Thoracic Oncology
    Stanford Health Care
    Palo Alto, California

    No financial interests or affiliations to disclose.

    Rasheda Persinger, NP-C
    Medical Oncology Nurse Practitioner
    The Sidney Kimmel Comprehensive Cancer Center
    Washington, DC

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Pfizer Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Guardant Health.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME/NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

    Release date: December 2020
    Expiration date: December 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):